Firstauthor [ref.no.] | Agents | Patients n | Dose of paclitaxel mg·m−2 | RRu% | Stage | Grade3–4 neutropeia % |
Nair 87 | Paclitaxe+Cisplati | 21 | 135, 3 h | 71 | E | 0 |
44 | 175, 3 h | 89 | E | 2 | ||
Grobn 88 | Paclitaxe+Carboplatin | 35 | 175, 3 h | 74 | L & E | 27 |
Gusson 89 | Paclitaxe+CisplatinEtoposide | 41 | 130, 3 h | 90 | E | 47 |
Kelly 90 | 28 | 175, 3 h | 83 | E | 82 | |
Kelly 91 | 90 | 175, 3 h | 56 | E | 35 | |
Mavroudis 92 | 62 | 175, 3 h | 50 | L & E | 44 | |
Birch 93 | Paclitaxe+Carboplatin+Etoposide | 84 | 200, 3 h | 89 | L & E | NR |
Fepri 94 | Docetaxe+Doxoubicine | 20 | NR | 10 | E | 17 |
Morbno 95 | Docetaxe+Cisplatin | 30 | 75 | 62 | E | 60 |
RRu: response rate in untreated patients
E: extensivestage
L: limited stage
NR: not reported